World's Best Scientists 2026 revealed!

Li Zhang publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Li Zhang sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

The last bar groups every scientist with 1,796 publications or more.

Li Zhang D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Li Zhang sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

The last bar groups every scientist with 217 D-Index or more.

Overview

Li Zhang is a researcher affiliated with Sun Yat-sen University in China, whose work is primarily situated in the field of medicine with a focus on oncology and pulmonary and respiratory medicine. Their research output includes substantial contributions to cancer research, molecular biology, and surgery.

Their research topics cover a variety of areas related to cancer and respiratory diseases, including:

  • Lung Cancer Treatments and Mutations
  • Lung Cancer Research Studies
  • Lung Cancer Diagnosis and Treatment
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • Colorectal Cancer Treatments and Studies
  • Head and Neck Cancer Studies

Frequent publication venues for Li Zhang include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Journal of Thoracic Oncology
  • Lung Cancer
  • Thoracic Cancer

Li Zhang has collaborated extensively with several researchers, including:

  • Wenfeng Fang
  • Yan Huang
  • Yunpeng Yang
  • Hongyun Zhao
  • Yuanyuan Zhao

Recent significant papers authored or coauthored by Li Zhang include:

  • Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial, 2021, The Lancet Oncology
  • Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706), 2021, Journal of Thoracic Oncology
  • Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant, 2024, JAMA
  • Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study, 2021, Journal of Clinical Oncology
  • Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study), 2021, Journal for ImmunoTherapy of Cancer

Li Zhang's work demonstrates a consistent focus on treatments and clinical trials for various types of cancer, particularly lung cancer and nasopharyngeal carcinoma, integrating chemotherapy, immunotherapy, targeted therapies, and biomarker analysis.

Best Publications

  • Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China

    Chaomin Wu;Xiaoyan Chen;Yanping Cai;Jia’an Xia

  • Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

    Caicun Zhou;Yi Long Wu;Gongyan Chen;Jifeng Feng

  • Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

    Keunchil Park;Eng Huat Tan;Ken O'Byrne;Li Zhang

  • Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine

    Chun Xiao Song;Keith E. Szulwach;Ye Fu;Qing Dai

  • Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis

    Pierre Blanchard;Pierre Blanchard;Anne Lee;Sophie Marguet;Julie Leclercq

  • Systematic comparison of constitutive promoters and the doxycycline-inducible promoter.

    Jane Yuxia Qin;Jane Yuxia Qin;Li Zhang;Kayla L. Clift;Imge Hulur

  • Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

    Nan Chen;Wenfeng Fang;Jianhua Zhan;Shaodong Hong

  • Development and Validation of a Nomogram for Predicting Survival in Patients With Resected Non–Small-Cell Lung Cancer

    Wenhua Liang;Li Zhang;Gening Jiang;Qun Wang

  • Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

    Yuankai Shi;Li Zhang;Xiaoqing Liu;Caicun Zhou

  • Sperm, but Not Oocyte, DNA Methylome Is Inherited by Zebrafish Early Embryos

    Lan Jiang;Jing Zhang;Jing-Jing Wang;Jing-Jing Wang;Lu Wang;Lu Wang

  • Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.

    Roy S Herbst;Yan Sun;Wilfried E E Eberhardt;Paul Germonpré

  • Risk of COVID-19 for patients with cancer.

    Hanping Wang;Li Zhang

  • Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.

    Jing Huang;Jianming Xu;Yun Chen;Wu Zhuang

  • Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

    Li Zhang;Yan Huang;Shaodong Hong;Yunpeng Yang

  • Nestin is required for the proper self-renewal of neural stem cells.

    Donghyun Park;Donghyun Park;Andy Peng Xiang;Frank Fuxiang Mao;Frank Fuxiang Mao;Li Zhang

  • Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

    D. Ross Camidge;Rafal Dziadziuszko;Solange Peters;Tony Mok

  • Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial

    Yi Long Wu;Jin Soo Lee;Sumitra Thongprasert;Chong Jen Yu

  • Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

    Wenfeng Fang;Yunpeng Yang;Yuxiang Ma;Shaodong Hong

  • Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer

    Ramaswamy Govindan;Aleksandra Szczesna;Myung Ju Ahn;Claus Peter Schneider

  • EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy

    Wenfeng Fang;Jianwei Zhang;Shaodong Hong;Jianhua Zhan

Frequent Co-Authors

Yi-Long Wu
Yi-Long Wu Guangdong Provincial People’s Hospital
Caicun Zhou
Caicun Zhou Tongji University
Bruce T. Lahn
Bruce T. Lahn University of Chicago
Tony Mok
Tony Mok Chinese University of Hong Kong
Gang Chen
Gang Chen Guangxi Medical University
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Jifeng Feng
Jifeng Feng Nanjing Medical University
Kenneth J. O'Byrne
Kenneth J. O'Byrne Queensland University of Technology
Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid
Michael Boyer
Michael Boyer University of Utah

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Are you exploring alternative career routes or flexible study options related to Medicine in the USA? Online education now offers many accredited pathways for both newcomers and experienced professionals in healthcare and related fields.

For registered nurses looking to advance their careers, consider targeted bridge programs like rn to fnp programs or rn to bsn online with no clinicals. These degrees provide a fast track to higher qualifications, often with flexible schedules and minimal on-site requirements.

If you’re interested in the science behind health and wellness, the best online food science degree programs can open doors to careers in nutrition, research, or food safety. Aspiring health administrators can pursue leadership by enrolling in whats the best online mha program for working adults, which is ideal for those balancing professional commitments.

With flexible online options, you can customize your learning journey, access diverse healthcare fields, and build a fulfilling career that makes a difference.

Best Scientists Citing Li Zhang

Trending Scientists

Recently Published Articles